ognizant Communication Corporation

REVIEWS IN ANALGESIA
An International Journal

AUTHOR AND SUBJECT INDEXES
Volumes 7-8

Author Index

Basbaum, A. I., 39 (v8)
Bassi, N., 97 (v7)
Benedetti, F., 129 (v7)
Budd, K., 1 (v8)

Chapman, V., 25 (v7)
Cohen, A. R., 97 (v7)
Colloca, L., 129 (v7)

Desai, S., 97 (v7)
Dubner, R., 57 (v8)

Espinosa, M. G., 97 (v7)

Farquhar-Smith, W. P., 103 (v8)
Farrell, M., 23 (v8)
Finn, D. P., 25 (v7)
Flynn, E. E., 97 (v7)
Franchetti, K. E., 97 (v7)

 Garzón, J., 41 (v7)
Gibson, S. J., 23 (v8)
Guan, Y., 57 (v8)
Guo, W., 57 (v8)

Jarvis, M. F., 1 (v7)

Kuriakose, A., 97 (v7)

Lam, S.-K. T., 97 (v7)
Liu, X. J., 145 (v7)
Ly, K. S., 97 (v7)

Malmberg, A. B., 119 (v7)
McGraw, M. J., 97 (v7)

Namazi, N. N., 97 (v7)
Nemeh, G. A., 97 (v7)

Oliva, C. D., 97 (v7)

 Pastakia, S. D., 97 (v7)

Raffa, R. B., 97 (v7), 71 (v8)
Rasmussen, K. G., 61 (v7)
Ren, K., 57 (v8)
Renn, C. L., 57 (v8)
Riley, K. M., 97 (v7)
Rothman, R. B., 83 (v7)

Sánchez-Blázquez, P., 41 (v7)
Sawynok, J., 145 (v7)
Sessle, B. J., 85 (v8)
Stevens, C. W., 69 (v7)

Tairu, O. A., 97 (v7)
Traynor, J. R., 11 (v8)

Xu, H., 83 (v7)

Zeitz, K. P., 119 (v7)

Subject Index

Acute responses, 145 (v7)
Adenosine, 1 (v7)
Age-related differences, 23 (v8)
AMPA, 57 (v8)
Amphibians, 69 (v7)
Analgesia, 97, v7), 71 (v8)
Antinociception, 97 (v7)
Antinociceptive effects, 25 (v7)
ATP, 1 (v7)

Behavior, 11 (v8)

Cannabinoid agonists, 25 (v7)
Cannabinoids, 25 (v7)
Central sensitization, 119 (v7), 145 (v7), 85 (v8)
Chronic pain, 1 (v7), 61 (v7), 85 (v8)

Dependence, 83 (v7)
Descending modulation, 57 (v8)

Efficacy, 11 (v8)
Electroconvulsive therapy, 61 (v7)
Endocannabinoids, 25 (v7), 103 (v8)
Endogenous pain modulation, 129 (v7)

Formalin test, 145 (v7)

GluR1, 57 (v8)
G-protein, 11 (v8)
G-protein signaling, 41 (v7)
[35S]GTP-g-S, 83 (v7)
 

 Hyperalgesia, 57 (v8)

Immune system, 1 (v8)
Immunomodulation, 103 (v8)
Immunosuppression, 1 (v8)
Inflammation, 57 (v8)
Injury, 119 (v7)

Kinase, 119 (v7)

Long-term responses, 145 (v7)

Mast cell, 103 (v8)
Molecular structure/function relationship, 1 (v8)
Morphine, 83 (v7)
Mu-opioids, 11 (v8)

Neurobiologic mechanisms, 61 (v7)
Neurophils, 103 (v8)
Nocebo effect, 129 (v7)
Nociceptive signaling, 1 (v7)

Opioid, 97 (v7)
Opioid analgesia, 41 (v7), 69 (v7), 1 (v8)
Opioid receptors, 69 (v7)
Opioid system, 129 (v7)
Orofacial pain, 85 (v8)

 Pain, 1 (v8)
Pain model, 145 (v7)
Pain perception, 23 (v8)
Pain relief, 71 (v8)
Pain treatment, 71 (v8)
Patent, 71 (v8)
Peripheral afferent neural activity, 145 (v7)
Peripheral sensitization, 119 (v7)
Persistent pain, 119 (v7)
Phase activity, 145 (v7)
Phosphoserine 831 GluR1, 57 (v8)
Placebo-controlled trials, 129 (v7)
Placebo effect, 129 (v7)
Plants, 97 (v7)
Potency, 11 (v8)
Preclinical tests, 97 (v7)
Primary depression syndrome, 61 (v7)
Primary pain syndrome, 61 (v7)
Psychosocial context, 129 (v7)
Purinergic modulation, 1 (v7)

Rana pipiens, 69 (v7)
Receptor-mediated analgesia, 25 (v7)
RGS proteins, 41 (v7)
Rostral ventromedial medulla, 57 (v8)

Signaling regulation, 41 (v7)

Therapeutic potential, 25 (v7)
Therapist-patient interaction, 129 (v7)
Tolerance, 83 (v7)
Treatment strategies, 23 (v8)
Trigeminal nociceptive pathways, 85 (v8)